ArticleChem2018
Overcoming Drug Resistance by Targeting Cancer Bioenergetics with an Activatable Prodrug.
Article in Chem, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- AChemical science · 2024Article
- Theranostic Fluorescent Probes.Chemical reviews · 2024Review
- Strategies for the development of stimuli-responsive small molecule prodrugs for cancer treatment.Frontiers in pharmacology · 2024Review
- Recent trends in emerging strategies for ferroptosis-based cancer therapy.Nanoscale advances · 2023Review
- An excipient-free "sugar-coated bullet" for the targeted treatment of orthotopic hepatocellular carcinoma.Chemical science · 2022Article
- Recapitulated Crosstalk between Cerebral Metastatic Lung Cancer Cells and Brain Perivascular Tumor Microenvironment in a Microfluidic Co-Culture Chip.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- High-throughput glycolytic inhibitor discovery targeting glioblastoma by graphite dots-assisted LDI mass spectrometry.Science advances · 2022Article
- Cancer Cell Membrane Biomimetic Mesoporous Nanozyme System with Efficient ROS Generation for Antitumor Chemoresistance.Oxidative medicine and cellular longevity · 2022Article
- Structurally Redesigned Bioorthogonal Reagents for Mitochondria-Specific Prodrug Activation.JACS Au · 2021Article
- Novel Approaches of Dysregulating Lysosome Functions in Cancer Cells by Specific Drugs and Its Nanoformulations: A Smart Approach of Modern Therapeutics.International journal of nanomedicine · 2021Review
- Fused isoselenazolium salts suppress breast cancer cell growth by dramatic increase in pyruvate-dependent mitochondrial ROS production.Scientific reports · 2020Article
- Stimuli-responsive prodrug-based cancer nanomedicine.EBioMedicine · 2020Review
- Stimulus-responsive surface-enhanced Raman scattering: a "Trojan horse" strategy for precision molecular diagnosis of cancer.Chemical science · 2020Article
- Nano-Platelets as an Oxygen Regulator for Augmenting Starvation Therapy Against Hypoxic Tumor.Frontiers in bioengineering and biotechnology · 2020Article
- Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.Journal of hematology & oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Nearly without exception, all known cancer chemotherapeutics elicit a resistance response over time. The resulting resistance is correlated with poor clinical outcomes. Here, we report an approach to overcoming resistance through reprogramming oncogene-directed alterations in mitochondrial metabolism before drug activation while simultaneously circumventing drug efflux pumps. Conjugate C1 increases cancer cell apoptosis and inhibits regrowth of drug-resistant tumors, as inferred from efficacy studies carried out in human cancer cells and in Dox-resistant xenograft tumor models. It also displays minimal whole-animal toxicity. These benefits are ascribed to an ability to evade chemoresistance by switching cancer cell metabolism back to normal mitochondrial oxidative phosphorylation while helping target the active Dox to first the mitochondrion and then the nucleus.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.